Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders

Nature Reviews Genetics

Volumn 3, Issue 12, 2002, Pages 954-966

  Desnick, Robert J ^a   Schuchman, Edward H ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; BETA N ACETYLHEXOSAMINIDASE A; GLUCOSYLCERAMIDASE; LYSOSOME ENZYME; RECOMBINANT ENZYME; SOMATOMEDIN B RECEPTOR;

ANIMAL MODEL; CLINICAL TRIAL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; ENZYME SYNTHESIS; ENZYME THERAPY; FABRY DISEASE; FAMILIAL DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LYSOSOME STORAGE DISEASE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SANDHOFF DISEASE;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; ENZYMES; FABRY DISEASE; HUMANS; LYSOSOMAL STORAGE DISEASES; MICE; MOLECULAR CHAPERONES;

ANIMALIA;

EID: 0036895451     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg963     Document Type: Review

References (112)

1. Scriver, C. R. et al. (eds) The Metabolic and Molecular Bases of Inherited Diseases (McGraw-Hill, New York, 2001) A four-volume textbook containing chapters on each LSD and other inherited metabolic diseases.
2. Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. JAMA 281, 249-254 (1999),
3. Holtzman, E. (ed) Lysosomes (Plenum, New York, 1989)
4. Kornfeld, S. & Mellman, I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5, 483-525 (1989).
5. Sabatini, D. D. & Adesnik, M. B. in The Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R. et al.) 475-484 (McGraw-Hill, New York, 2001).
6. Kornfeld, S. & Sly, W. S. in The Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R. et al.) 3469-3482 (McGraw-Hill, New York, 2001).
7. de Duve, C. From cytases to lysosomes. Fed. Proc. 23, 1045 (1964). In this paper, de Duve first proposes that ERT could be used to treat LSDs.
8. Barton, R. W. & Neufeld, E. F. The Hurler corrective factor. Purification and some properties. J. Biol. Chem. 246, 7773-7779 (1971).
9. Hickman, S. & Neufeld, E. F. A hypothesis for I-cell diseases defective hydrolases that do not enter lysosomes. Biochem. Biophys. Res. Commun 49, 992-999 (1972).
10. Kaplan, A., Achord, D. T. & Sly, W. S. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl. Acad. Sci. USA 74, 2026-2030 (1977).
11. Sahagian, G. G., Distler, J. & Jourdian, G. W. Characterization of a membrane-associated receptor from bovine liver that binds phosphomannosyl residues of bovine testicular β-galactosidase. Proc. Natl. Acad. Sci. USA 78, 4289-4293 (1981).
12. Kornfeld, S. Lysosomal enzyme targeting. Biochem. Soc. Trans. 18, 367-374 (1990). A seminal review that describes the biosynthesis of N-linked oligosaccharides on lysosomal enzymes, and the M6P-receptor-mediated pathway for the delivery of lysosomal enzymes to the lysosome.
13. Hille-Rehfeld, A. Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. Biochem. Biophys. Acta 1241, 177-194 (1995).
14. Kornfeld, S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu. Rev. Biochem. 61, 307-330 (1992).
15. Frustaci, A. et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N. Engl. J. Med 345, 25-32 (2001). First clinical example of EET for an LSD. Administration of galactose as a reversible competitive inhibitor rescued mutant α-galactosidase activity and improved heart function.
16. Treacy, E. P., Valle, D. & Scriver, C. R. in The Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R. et al.) 175-191 (McGraw-Hill, New York, 2001).
17. Sly, W. S. & Vogler, C. Brain-directed gene therapy for lysosomal storage disease: Going well beyond the blood-brain barrier. Proc. Natl. Acad. Sci. USA 99, 5760-5762 (2002).
18. Cabrera-Salazar, M. A., Novelli, E. & Barranger, J. A. Gene therapy for the lysosomal storage disorders. Curr. Opin. Mol. Ther. 4, 349-358 (2002).
19. Porter, M. T., Fluharty, A. L. & Kihara, H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 172, 1263-1265 (1971).
20. O'Brien, J. S., Miller, A. L. Loverde, A. W. & Veath, M. L. Sanfilippo disease type B: Enzyme replacement and metabolic correction in cultured fibroblasts. Science 181, 753-755 (1973).
21. Cantz, M. & Kresse, H. Sandhoff disease: Defective glycosaminoglycan catabolism in cultured fibroblasts and its correction by β-N-acetylhexosaminidase. Eur. J. Biochem. 47, 581-590 (1974).
22. Desnick, R. J. (ed.) Enzyme Therapy in Genetic Diseases Vol. 2 (Alan R. Liss, Inc., New York, 1980).
23. Desnick, R. J. & Grabowski, G. in Advances in Human Genetics Vol. 11 (eds Harris, H. & Hirschhorn, K.) 281-349 (Plenum, New York, 1981).
24. Desnick, R. J. (ed.) Treatment of Genetic Diseases (Churchill Livingstone, New York, 1991).
25. Johnson, W. G. et al. in Enzyme Therapy in Genetic Diseases (eds Desnick, R. J., Bernlohr, R. W. & Krivit, W.) 120-124 (Williams & Wilkins, Baltimore, Maryland, 1973).
26. de Barsy, T., Jacquemin, P., van Hoof, F. & Hers, H. G. in Enzyme Therapy in Genetic Diseases (eds Desnick, R. J., Bernlohr, R. W. & Krivit, W.) 184-190 (Williams & Wilkins, Baltimore, Maryland, 1973).
27. Brady, R. O. et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N. Engl. J. Med. 289, 9-14 (1973).
28. Desnick, R. J., Dean, K. J., Grabowski, G., Bishop, D. F. & Sweeley, C. C. Enzyme therapy in Fabry disease: Differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic α-galactosidase A isozymes. Proc. Natl. Acad. Sci. USA 76, 5326-5330 (1979).
29. Brady, R. O., Pentchev, P. G., Gal, A. E., Hibbert, S. R. & Dekaban, A. S. Replacement therapy for inherited enzyme deficiency: Use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med. 291, 989-993 (1974).
30. Desnick, R. J., Bernlohr, R. W. & Krivit, W. (eds) Enzyme Therapy in Genetic Diseases (Williams & Wilkins, Baltimore, Maryland, 1973).
31. von Specht, B. U. et al. Enzyme replacement in Tay - Sachs disease. Neurology 29, 848-854 (1979).
32. Rattazzi, M. C. & Dobrrenis, K. in Treatment of Genetic Diseases (ed. Desnick, R. J.) 131-152 (Churchill Livingstone, New York, 1991).
33. Dobrenis, K., Joseph, A. & Rattazzi, M. C. Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin. Proc. Natl. Acad. Sci. USA 89, 2297-2301 (1992).
34. Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M. & Brady, R. O. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. USA 87, 1913-1916 (1990). This article convincingly describes the effectiveness of ERT for type I Gaucher disease. These studies provided the proof-of-principle that ERT can reverse the underlying pathology in a human LSD.
35. Barton, N.W. et al. Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324, 1464-1470 (1991).
36. Brady, R. O. & Barton, N. W. in Treatment of Genetic Diseases (ed. Desnick, R. J.) 153-168 (Churchill Livingstone, New York, 1991).
37. Weinreb, N. J. et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am. J. Med. 113, 112-119 (2002).
38. Grabowski, G. A., Leslie, N. & Wenstrup, R. Enzyme therapy for Gaucher disease: The first 5 years. Blood Rev. 12, 115-133 (1998).
39. Mistry, P. K. Gaucher's disease: A model for modern management of a genetic disease. J. Hepatol. 30, 1-5 (1999).
40. Ioannou, Y. A., Bishop, D. F. & Desnick, R. J. Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J. Cell Biol. 119, 1137-1150 (1992).
41. Bijvoet, A. G. et al. Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum. Mol. Genet. 8, 2145-2153 (1999).
42. Miranda, S. R. et al. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14, 1988-1995 (2000).
43. Ioannou, Y. A., Zeidner, K. M., Gordon, R. E. & Desnick, R J. Fabry disease: Preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 68, 14-25 (2001).
44. Selden, R. F., Skoskiewicz, M. J., Howie, K, B., Russell, P. S. & Goodman, H. M. Implantation of genetically engineered fibroblasts into mice: Implications for gene therapy. Science 236, 714-718 (1987).
45. Cramer, C. L. et al. Bioproduction of human enzymes in transgenic tobacco. Am. NY Acad. Sci. 792, 62-71 (1996).
46. Desnick, R. J., Patterson, D. F. & Scarpelli, D. G. Animal Models of Inherited Metabolic Diseases (Alan R, Liss, Inc., New York, 1982).
47. Sango, K. et al. Mouse models ofTay - Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11, 170-176 (1995).
48. Platt, F. M. & Butters, T. D. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem. Pharmacol. 66, 421-430 (1998).
49. Wang, A. M. et al. Generation of a mouse model with α-galactosidase A deficiency. Am. J. Hum. Genet. 59, A208 (1996).
50. Ohshima, T. et al. α-galactosidase A deficient mice: A model of Fabry disease. Proc. Natl. Acad. Sci. USA 94, 2540-2544 (1997).
51. Horinouchi, K., Sakiyama, T., Pereira, L., Lalley, P. A. & Schuchman, E. H. Mouse models of Niemann-Pick disease: Mutation analysis and chromosomal mapping rule out the type A and B forms. Genomics 18, 450-451 (1993).
52. Otterbach, B. & Stoffel, W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81, 1053-1061 (1995).
53. Hess, B. et al. Phenotype of arylsulfatase A-deficient mice: Relationship to human metachromatic leukodystrophy. Proc. Natl. Acad Sci. USA 93, 14821-14826 (1996).
54. Clarke, L. A. et al. Murine mucopolysaccharidosis type I: Targeted disruption of the murine α-L-iduronidase gene. Hum. Mol. Genet. 6, 503-511 (1997).
55. Li, H. H. et al. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding α-N-acetylglucosaminidase. Proc. Natl. Acad. Sci. USA 96, 14505-14510 (1999).
56. Evers, M. et al. Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc. Natl. Acad. Sci. USA 93, 8214-8219 (1996).
57. Bijvoet, A. G. et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum. Mol. Genet. 7, 53-82 (1998).
58. Raben, N. et al. Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273, 19086-19092 (1998).
59. Du, H. et al. Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum. Mol. Genet 10, 1639-1648 (2001).
60. Bhaumik, M. et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9, 1389-1396 (1999).
61. Vogler, C. et al. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in β-glucuronidase-deficient mice. Am. J. Pathol. 136, 207-217 (1990).
62. Tybulewicz, V. L. et al. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357, 407-410 (1992).
63. Sidransky, E., Sherer, D. M. & Ginns, E. I. Gaucher disease in the neonate: A distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr. Res 32, 494-498 (1992).
64. Jeyakumar, M. et al. An inducible mouse model of late onset Tay-Sachs disease. Neurobiol. Dis. 10, 201 (2002).
65. Takahashi, H. et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Natl. Aced. Sci. USA 99, 13777-13782 (2002).
66. Yuziuk, J. A. et al. Specificity of mouse GM2 activator protein and β-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2. J. Biol. Chem. 273, 66-72 (1998).
67. Brooks, D. A. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab, 68, 268-275 (1999).
68. Fan, J. Q., Ishii, S., Asano, N. & Suzuki, Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Med. 5, 112-115 (1999). The first demonstration of EET for a LSD, in which a substrate inhibitor was used to rescue mutant α-galactosidase A glycopeptides from ER degradation and transport them to the lysosome.
69. Marathe, S. et al. Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: Relationship between brain intra-lysosomal enzyme activity and central nervous system function. Hum. Mol. Genet. 9, 1967-1976 (2000).
70. Altarescu, G, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr. 138, 539-547 (2001).
71. Aoki, M. et al. Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb. Eur. J. Pediatr. 160, 63-64 (2001).
72. Neufeld, E. F. & Muenzer, J. In The Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R. et al.) 3421-3452 (McGraw-Hill, New York, 2001).
73. Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285, 2743-2749 (2001).
74. Eng, C. M. et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345, 9-16 (2001). This paper reported the results of the largest clinical trial in a LSD, which showed that ERT reversed the fundamental pathology of Fabry disease and was safe and effective for treatment.
75. Eng, C. M. et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 88, 711-722 (2001).
76. Schiffmann, R. et al. Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97, 365-370 (2000).
77. Van den Hout, H. et al. First clinical test with recombinant human α-glucosidase from rabbit milk shows therapeutic effect in Pompe disease. Am. J. Hum. Genet. 67(Suppl.2), 6 (2000).
78. Van den Hout, J. M. et al. Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J. Inherit. Metab. Dis. 24, 266-274 (2001).
79. Kishnani, P. et al. Treatment of classical infantile Pompe disease (CIPD) with recombinant human acid α glucosidase (rhGAA): Preliminary 6 month data from a phase 2 study. Am. J. Hum. Genet. 71, 582 (2002).
80. Amalfitano, A. et al. Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genet. Med. 3, 132-138 (2001).
81. van der Ploeg, A. T. et al. Preliminary findings in patients with late onset Pompe's disease treated with recombinant human α-glucosidase from rabbit milk. J. Inherit. Metab Dis. 25, 118 (2002).
82. Kakkis, E. D. et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182-188 (2001).
83. Beck, M. et al. A phase 3 study of rhlDUA enzyme therapy for MPS I. J. Inherit. Metab. Dis. 25, 120 (2002).
84. Muenzer, J., Towle, D., Calikoglu, M. & McCandlless, S. A phase I/II clinical study evaluating the safety and clinical activity of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Am. J. Hum. Genet. 71, 582 (2002).
85. Harmatz, P. et al. A phase I/II study of enzyme replacement therapy (ERT) for mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome): 48 Week progress report. Am. J. Hum. Genet. 71, 582 (2002).
86. Bonten, E. J. et al. Effective enzyme replacement therapy of murine galactosialidosis using insect cell-expressed PPCA and neuraminidase. Am. J. Hum. Genet. 71, 420 (2002).
87. Vogler, C. et al. Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr. Res. 45, 838-844 (1999).
88. Sands, M. S. et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated β-glucuronidase in the murine model of mucopolysaccharidosis VII. J. Biol. Chem. 276, 43160-43165 (2001).
89. Desnick, R. J., Ioannou, Y. A. & Eng, C. M. in The Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R. et al.) 3733-3774 (McGraw-Hill, New York, 2001).
90. Miranda, S. R., Erlich, S., Friedrich, V. L. Jr, Gatt, S. & Schuchman, E. H. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther. 7, 1768-1776 (2000).
91. Hampton, R. ER-associated degradation in protein quality control and cellular regulation. Curr. Opin. Cell Biol. 14, 476 (2002).
92. Wagner, E. & Lykke-Andersen, J. mRNA surveillance: The perfect persist. J. Cell Sci. 115, 3033-3038 (2002).
93. Kerem, B. et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 245, 1073-1080 (1989).
94. Sato, S., Ward, C. L., Krouse, M. E., Wine, J. J. & Kopito, R. R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271, 635-638 (1996).
95. Cox, D. W. in The Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R. et al.) 5559-5586 (McGraw-Hill, New York, 2001).
96. 1-antitrypsin deficiency - A model for conformational diseases. N Engl. J. Med. 346, 46-53 (2002).
97. Loo, T. W. & Clarke, D. M. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272, 709-712 (1997). One of the first descriptions of EET showing that substrates and modulator compounds bound to the multidrug resistance protein could rescue mutant proteins and transport them to the plasma membrane.
98. 1-AT deficiency. Proc. Natl. Acad. Sci. USA 97, 1796-1801 (2000).
99. Welch, W. J. & Brown, C. R. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1, 109-115 (1996).
100. Brown, C. R., Hong-Brown, L. Q., Biwersi, J., Verkman, A. S. & Welch, W. J. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1, 117-125 (1996).
101. Rubenstein, R, C., Egan, M. E. & Zeitlin, P. L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR. J. Clin. Invest. 100, 2457-2465 (1997).
102. Morello, J. P. et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105, 887-895 (2000).
103. Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
104. Welch, W. J. & Howard, M. Antagonists to the rescue. J. Clin. Invest. 105, 853-854 (2000).
105. Morello, J. P., Petaja-Repo, U. E., Bichet, D. G. & Bouvier, M. Pharmacological chaperones: A new twist on receptor folding. Trends Pharmacol. Sci. 21, 466-469 (2000).
106. Okumiya, T. et al. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem. Biophys. Res. Commun. 214, 1219-1224 (1995).
107. Asano, N. et al. In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojinimycin and its derivatives. Eur. J. Biochem. 267, 4179-4186 (2000).
108. Desnick, R. J., Thorpe, S. R. & Fiddler, M. B. Toward enzyme therapy for lysosomal storage disease. Physiol. Rev, 56, 57-99 (1976).
109. Doebber, T. W. et al. Enhanced macrophage uptake of synthetically glycosylated human placental β-glucocerebrosidase. J. Biol. Chem, 257, 2193-2199 (1982).
110. Brady, R. O., Barranger, J. A., Gal, A. E., Pentchev, P. G. & Furbish, F. S. in Enzyme Therapy in Genetic Disease Vol. 2 (ed. Desnick, R. J.) 361-368 (Alan R. Liss, Inc., New York, 1980).
111. Grabowski, G. A. et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122, 33-39 (1995).
112. Loldish, H. et al. in Molecular Cell Biology 4th Edn., 721 (W. H. Freeman & Co., New York, 2000).